• 微博
  • 微信微信二维码

广东省人民政府首页  >  要闻动态  >  广东要闻

康臣药业(1681.HK):2017年EPS同比大增43.6%,新型品牌中医药的腾飞

来源: 南方日报网络版     时间: 2019年05月27日 12:17:55
【字体:

幸运飞艇新手怎么玩平台直属招商客服QQ【7915171】诚招代理龙虎和龙虎1赔2.211合1赔9.95,定位胆1赔9.95腾讯5,10分欢乐生肖,最高返水100反9快,最高赔率,正规信誉大平台平台24h提供注册及登录。康臣药业(1681.HK):2017年EPS同比大增43.6%,新型品牌中医药的腾飞

季后赛哪5人面临压力最大?乐福唐斯在列,哈登最需正名 限价之后的深圳楼市充满怪象,楼市到底怎么了? 2017-2018赛季五大“王”:哈登30.4分获得分王,威少荣膺助攻王 国乒功勋名将退役!恩师马琳被除名,自己下海经商直言脑子不够用 夜读丨每一种磨难,都是一次成长的机会 感人!刘国梁秦志戬祝福刘诗雯生日快乐 刘国梁祝刘诗雯为国立功 滴滴美团各被罚十万, 是“狗咬狗”引来的自作自受吗? 最新夺冠赔率:勇士力压火箭居首 骑士排名第三 三双+最佳新秀!西蒙斯未来生涯有3可能:开发2技能可接管联盟 摩拜单车被美团收购, 那创始人胡炜炜能从里面拿走多少钱? 一笑倾城!中国女排又一女神抵达全明星活动现场,知性大方气质佳 重返NBA!劳森与奇才签约至赛季结束 将打季后赛 劳森火线签约奇才或证山东输球不冤 CBA成重返联盟跳板 曼城魔鬼赛场最后一战不容有失 若遭4连败夺英超也是耻辱 四大联赛欲包揽欧战赛事4强席位 边缘联赛打响荣誉保卫战

(原)(标)(题)(:康)(臣)(药)(业)((1681.HK):2017年)(EPS同)(比)(大)(增)(43.6%,新)(型)(品)(牌)(中)(医)(药)(的)(腾)(飞)(
作)(者)(:格)(隆)(汇)(·思)(源)(
2018年)(3月)(21日)(,康)(臣)(药)(业)(公)(布)(2017年)(财)(报)(,全)(年)(总)(收)(入)(人)(民)(币)(16.6亿)(元)(,同)(比)(增)(长)(约)(35.7%,股)(东)(应)(占)(溢)(利)(人)(民)(币)(3.96亿)(元)(,同)(比)(增)(长)(约)(28.8%,EPS同)(比)(增)(长)(43.6%至)(0.46,派)(期)(末)(股)(息)(0.1港)(元)(,同)(比)(上)(涨)(100%。
一)(、业)(绩)(回)(顾)(
康)(臣)(药)(业)(的)(业)(务)(板)(块)(比)(较)(清)(晰)(,一)(个)(是)(上)(市)(主)(体)(的)(传)(统)(业)(务)(,一)(个)(是)(并)(购)(的)(玉)(林)(制)(药)(,2017年)(两)(者)(都)(取)(得)(了)(稳)(健)(的)(增)(长)(。
1)主)(体)(业)(务)(
主)(体)(业)(务)((不)(含)(玉)(林)(制)(药)(分)(部)()经)(营)(规)(模)(突)(破)(人)(民)(币)(10亿)(元)(,增)(长)(速)(度)(继)(续)(挤)(身)(中)(国)(医)(药)(行)(业)(前)(列)(。其)(中)(,康)(臣)(药)(业)(肾)(病)(药)(物)(的)(销)(售)(收)(入)(于)(2017年)(达)(到)(人)(民)(币)(8.15亿)(元)(,较)(去)(年)(同)(比)(增)(长)(约)(11.0%,龙)(头)(产)(品)(尿)(毒)(清)(颗)(粒)(依)(然)(强)(势)(维)(持)(肾)(病)(口)(服)(现)(代)(中)(成)(药)(市)(场)(的)(领)(导)(地)(位)(,且)(在)(新)(医)(保)(目)(录)(中)(乙)(类)(转)(甲)(类)(,为)(未)(来)(的)(销)(售)(提)(供)(有)(利)(环)(境)(。
医)(用)(成)(像)(对)(比)(剂)(市)(场)(的)(领)(先)(产)(品)(钆)(喷)(酸)(葡)(胺)(注)(射)(液)(销)(售)(额)(于)(今)(年)(为)(人)(民)(币)(1.19亿)(元)(,较)(去)(年)(同)(比)(下)(降)(约)(4.2%,但)(仍)(然)(维)(持)(在)(磁)(共)(振)(成)(像)(对)(比)(剂)(产)(品)(线)(的)(稳)(固)(地)(位)(。
妇)(儿)(产)(品)(是)(本)(年)(度)(新)(增)(加)(的)(一)(个)(过)(亿)(品)(类)((右)(旋)(糖)(酐)(铁)(口)(服)(液)(),考)(虑)(到)(妇)(儿)(产)(品)(中)(补)(铁)(产)(品)(的)(庞)(大)(市)(场)(,本)(公)(司)(新)(设)(团)(队)(专)(营)(右)(旋)(糖)(酐)(铁)(口)(服)(液)(。
2)玉)(林)(制)(药)(
玉)(林)(制)(药)(全)(年)(实)(现)(业)(务)(收)(入)(约)(人)(民)(币)(6亿)(元)(,同)(比)(增)(长)(约)(23.0%,其)(税)(后)(利)(润)(约)(人)(民)(币)(1.23亿)(元)(,同)(比)(增)(长)(约)(52.0%。主)(品)(种)(湿)(毒)(清)(系)(列)(销)(售)(收)(入)(约)(人)(民)(币)(2.21亿)(元)(,同)(比)(增)(长)(约)(13.3%;正)(骨)(水)(销)(售)(收)(入)(约)(人)(民)(币)(1.78亿)(元)(,同)(比)(增)(长)(约)(37.2%;新)(增)(加)(的)(过)(亿)(产)(品)(鸡)(骨)(草)(系)(列)(销)(售)(收)(入)(约)(人)(民)(币)(1.03亿)(元)(,同)(比)(增)(长)(约)(24.4%。
2017年)(10月)(,玉)(林)(制)(药)(启)(动)(国)(内)(A股)(上)(市)(可)(行)(性)(的)(研)(究)(,玉)(林)(制)(药)(「整)(体)(搬)(迁)(入)(园)(项)(目)(」也)(在)(稳)(步)(推)(进)(,目)(前)(已)(完)(成)(园)(区)(南)(区)(2万)(平)(方)(米)(的)(仓)(库)(的)(封)(顶)(工)(作)(。玉)(林)(制)(药)(新)(地)(点)(规)(划)(用)(地)(600多)(亩)(,计)(划)(总)(投)(资)(额)(逾)(人)(民)(币)(10亿)(元)(,准)(备)(按)(照)(「整)(体)(规)(划)(、分)(期)(实)(施)(」的)(原)(则)(分)(三)(期)(进)(行)(建)(设)(。投)(产)(后)(,产)(能)(将)(是)(目)(前)(的)(6倍)(。
总)(体)(来)(看)(,公)(司)(的)(基)(本)(面)(相)(当)(扎)(实)(,原)(来)(的)(拳)(头)(产)(品)(尿)(毒)(清)(保)(持)(增)(长)(,且)(医)(保)(乙)(转)(甲)(基)(本)(可)(以)(保)(障)(未)(来)(几)(年)(的)(销)(售)(增)(长)(情)(况)(,而)(且)(在)(这)(个)(类)(目)(,目)(前)(看)(不)(到)(强)(力)(的)(竞)(争)(对)(手)(,作)(为)(公)(司)(绝)(对)(的)(核)(心)(产)(品)(,稳)(住)(了)(,公)(司)(的)(基)(本)(面)(就)(是)(稳)(健)(的)(,在)(处)(方)(中)(药)(大)(面)(积)(承)(压)(的)(背)(景)(下)(,很)(不)(容)(易)(。
尿)(毒)(清)(稳)(住)(基)(本)(盘)(之)(后)(,玉)(林)(制)(药)(改)(制)(之)(后)(持)(续)(的)(释)(放)(弹)(性)(,玉)(林)(制)(药)(拥)(有)(9种)(剂)(型)(,73个)(品)(规)(,其)(中)(独)(家)(品)(种)(20个)(、地)(理)(标)(志)(产)(品)(1个)(、重)(要)(保)(护)(品)(种)(12个)(,未)(来)(管)(线)(的)(挖)(掘)(潜)(力)(足)(够)(大)(,从)(目)(前)(规)(划)(的)(远)(期)(产)(能)(扩)(大)(6倍)(来)(看)(,管)(理)(层)(有)(足)(够)(的)(信)(心)(。
因)(此)(,就)(存)(量)(业)(务)(来)(看)(,当)(前)(的)(在)(售)(管)(线)(绝)(大)(部)(分)(都)(在)(销)(量)(爬)(升)(阶)(段)(,也)(有)(足)(够)(的)(潜)(力)(品)(种)(可)(供)(挖)(掘)(,作)(为)(中)(药)(企)(业)(来)(讲)(,已)(经)(很)(难)(得)(了)(,这)(种)(都)(是)(实)(实)(在)(在)(的)(临)(床)(用)(药)(和)(OTC产)(品)(,是)(未)(来)(中)(药)(发)(展)(的)(正)(确)(路)(线)(,靠)(中)(药)(注)(射)(剂)(、中)(成)(药)(打)(天)(下)(的)(日)(子)(已)(经)(一)(去)(不)(复)(返)(了)(...
健)(康)(的)(在)(售)(管)(线)(,就)(是)(最)(扎)(实)(的)(基)(本)(面)(。
二)(、财)(报)(重)(点)(
这)(次)(财)(报)(中)(,有)(一)(个)(变)(化)(必)(然)(会)(引)(起)(专)(业)(投)(资)(者)(的)(关)(注)(,就)(是)(公)(司)(多)(年)(健)(康)(的)(经)(营)(性)(现)(金)(流)(突)(然)(转)(坏)(了)(,在)(营)(收)(增)(速)(35.7%的)(背)(景)(下)(,经)(营)(性)(现)(金)(流)(减)(少)(了)(43.9%,这)(个)(背)(离)(很)(奇)(怪)(。
这)(个)(现)(象)(如)(果)(是)(了)(解)(行)(业)(背)(景)(的)(,大)(概)(都)(能)(想)(到)(是)(什)(么)(情)(况)(,1)两)(票)(制)(的)(落)(地)(,把)(原)(来)(作)(为)(缓)(冲)(层)(的)(各)(级)(代)(理)(给)(干)(掉)(了)(,工)(业)(板)(块)(直)(接)(对)(接)(大)(商)(业)(公)(司)(,去)(掉)(了)(缓)(冲)(层)(,工)(业)(板)(块)(普)(遍)(的)(都)(出)(现)(了)(应)(收)(放)(大)(的)(情)(况)(,这)(个)(是)(行)(业)(的)(共)(性)(情)(况)(;2)并)(购)(的)(玉)(林)(制)(药)(主)(要)(的)(业)(务)(集)(中)(在)(OTC领)(域)(,主)(要)(对)(接)(的)(是)(零)(售)(终)(端)(,这)(个)(业)(态)(本)(来)(就)(需)(要)(压)(货)(,再)(者)(,零)(售)(连)(锁)(集)(中)(度)(越)(来)(越)(高)(,信)(用)(度)(提)(高)(了)(,授)(信)(放)(大)(很)(正)(常)(;3)最)(后)(就)(是)(中)(药)(的)(价)(格)(波)(动)(了)(,上)(市)(公)(司)(屯)(库)(存)(了)(,中)(药)(的)(价)(格)(波)(动)(,你)(懂)(得)(...
所)(以)(,行)(业)(结)(构)(和)(业)(务)(结)(构)(的)(变)(化)(叠)(加)(备)(货)(周)(期)(,这)(个)(财)(报)(周)(期)(的)(经)(营)(性)(现)(金)(流)(有)(所)(下)(降)(,经)(营)(性)(现)(金)(流)(的)(下)(降)(其)(实)(是)(管)(理)(层)(在)(业)(务)(上)(激)(进)(的)(结)(果)(,但)(是)(具)(体)(去)(看)(应)(收)(帐)(款)(的)(账)(期)(,93%的)(应)(收)(都)(维)(持)(在)(3个)(月)(以)(内)(的)(,账)(期)(相)(对)(健)(康)(。
除)(了)(前)(文)(提)(及)(的)(相)(对)(健)(康)(的)(在)(售)(管)(线)(,康)(臣)(特)(色)(的)(在)(研)(管)(线)(也)(为)(未)(来)(提)(供)(弹)(性)(。2017年)(,广)(州)(康)(臣)(「博)(士)(后)(科)(研)(工)(作)(站)(」引)(进)(两)(名)(博)(士)(进)(站)(开)(展)(研)(究)(。糖)(尿)(病)(肾)(病)(新)(药)(项)(目)(,「黄)(芪)(散)(微)(丸)(」,被)(授)(予)(国)(家)(「重)(大)(新)(药)(创)(制)(」项)(目)(资)(金)(资)(助)(人)(民)(币)(180万)(,这)(是)(本)(公)(司)(首)(次)(获)(批)(国)(家)(级)(科)(研)(课)(题)(资)(助)(,而)(该)(项)(目)(于)(2018年)(3月)(已)(经)(获)(得)(国)(家)(食)(品)(药)(品)(监)(督)(管)(理)(总)(局)(药)(品)(审)(评)(中)(心)(的)(临)(床)(试)(验)(批)(件)(。
本)(集)(团)(其)(他)(重)(点)(研)(发)(项)(目)(聚)(焦)(「超)(声)(微)(泡)(造)(影)(剂)(」和)(「正)(骨)(水)(二)(次)(开)(发)(」;超)(声)(微)(泡)(项)(目)(完)(成)(部)(分)(处)(方)(研)(究)(、工)(艺)(参)(数)(优)(化)(和)(生)(产)(线)(建)(设)(,短)(期)(内)(将)(进)(入)(临)(床)(实)(验)(;正)(骨)(水)(的)(新)(剂)(型)(水)(凝)(胶)(巴)(布)(制)(剂)(即)(将)(开)(展)(中)(试)(,预)(计)(将)(于)(2019年)(取)(得)(临)(床)(批)(件)(。
如)(果)(现)(实)(点)(,只)(看)(在)(研)(管)(线)(中)(最)(快)(上)(市)(,很)(可)(能)(是)(极)(具)(特)(色)(的)(专)(科)(品)(种)(:超)(声)(微)(泡)(造)(影)(剂)(,化)(药)(首)(仿)(,用)(于)(超)(声)(心)(动)(图)(检)(查)(、大)(/小)(血)(管)(多)(普)(勒)(检)(查)(,这)(类)(药)(物)(代)(谢)(快)(、观)(察)(期)(短)(,临)(床)(推)(进)(速)(度)(快)(,还)(是)(进)(口)(替)(代)(,相)(信)(技)(术)(攻)(关)(后)(获)(批)(难)(度)(不)(大)(,预)(期)(2018年)(10月)(申)(报)(临)(床)(,2019年)(上)(市)(。一)(旦)(这)(个)(品)(种)(上)(市)(,微)(泡)(这)(个)(特)(色)(技)(术)(平)(台)(可)(能)(就)(像)(石)(药)(的)(脂)(质)(体)(平)(台)(、丽)(珠)(的)(微)(球)(平)(台)(一)(样)(,迅)(速)(复)(制)(到)(其)(他)(品)(种)(,走)(改)(剂)(型)(打)(差)(异)(化)(的)(路)(线)(。
康)(臣)(手)(里)(的)(玉)(林)(制)(药)(,是)(一)(个)(有)(故)(事)(的)(品)(牌)(,前)(身)(为)(创)(立)(于)(1956年)(的)(玉)(林)(制)(药)(厂)(,是)(国)(家)(商)(务)(部)(首)(批)(认)(定)(为)(“中)(华)(老)(字)(号)(”的)(企)(业)(,有)(足)(够)(的)(品)(牌)(故)(事)(可)(讲)(,而)(且)(身)(处)(OTC领)(域)(,受)(到)(医)(保)(控)(费)(的)(压)(力)(比)(较)(小)(,改)(制)(这)(两)(年)(,康)(臣)(已)(经)(证)(明)(了)(他)(的)(管)(理)(能)(力)(,接)(下)(来)(的)(事)(情)(交)(给)(时)(间)(就)(好)(了)(。
结)(语)(:
管)(理)(层)(给)(的)(业)(绩)(指)(引)(是)(未)(来)(几)(年)(维)(持)(20%以)(上)(的)(符)(合)(增)(长)(率)(,现)(价)(对)(应)(2017年)(静)(态)(市)(盈)(率)(为)(15.15倍)(,与)(同)(行)(业)(公)(司)(对)(比)(,估)(值)(较)(低)(。
自)(2017年)(6月)(起)(,总)(市)(值)(始)(终)(保)(持)(50亿)(港)(元)(以)(上)(,2018年)(3月)(康)(臣)(药)(业)(终)(于)(进)(入)(深)(港)(通)(,进)(入)(之)(后)(,南)(下)(资)(金)(也)(开)(始)(流)(入)(,在)(这)(个)(业)(绩)(预)(期)(下)(,康)(臣)(和)(同)(行)(业)(的)(估)(值)(差)(会)(随)(着)(流)(动)(性)(的)(改)(善)(逐)(步)(修)(复)(。
返)(回)(搜)(狐)(,查)(看)(更)(多)(责)(任)(编)(辑)(:
)


相关文章

版权所有:南方新闻网 粤ICP备05070829 网站标识码4400000131
主办:南方新闻网 协办:广东省经济和信息化委员会 承办:南方新闻网
建议使用1024×768分辨率 IE7.0以上版本浏览器